Cargando…

Treatment use and satisfaction among patients with psoriasis and psoriatic arthritis: results from the NORdic PAtient survey of Psoriasis and Psoriatic arthritis (NORPAPP)

BACKGROUND: There are scarce data in Scandinavia about treatment satisfaction among patients with psoriasis (PsO) and/or psoriatic arthritis (PsA). The number of patients receiving systemic treatment is unknown. OBJECTIVE: To describe patients’ experience of treatments for PsO/PsA in Sweden, Denmark...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tveit, K.S., Duvetorp, A., Østergaard, M., Skov, L., Danielsen, K., Iversen, L., Seifert, O.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Psoriasis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587823/ https://www.ncbi.nlm.nih.gov/pubmed/30242921 http://dx.doi.org/10.1111/jdv.15252

Ejemplares similares

Quality of life and contact with healthcare systems among patients with psoriasis and psoriatic arthritis: results from the NORdic PAtient survey of Psoriasis and Psoriatic arthritis (NORPAPP)
por: Duvetorp, A., et al.
Publicado: (2019)

Utilization of the validated Psoriasis Epidemiology Screening Tool to identify signs and symptoms of psoriatic arthritis among those with psoriasis: a cross‐sectional analysis from the US‐based Corrona Psoriasis Registry
por: Mease, P.J., et al.
Publicado: (2019)

Tofacitinib in psoriatic arthritis patients: skin signs and symptoms and health‐related quality of life from two randomized phase 3 studies
por: Merola, J.F., et al.
Publicado: (2020)

The experience of pain and redness in patients with moderate to severe plaque psoriasis
por: Martin, Mona L., et al.
Publicado: (2015)

Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world setting
por: Bonafede, Machaon, et al.
Publicado: (2013)

Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients
por: Gerdes, S., et al.
Publicado: (2019)

GENETICS OF PSORIASIS AND PSORIATIC ARTHRITIS
por: Chandran, Vinod
Publicado: (2010)

Freedom from disease in psoriasis: a Delphi consensus definition by patients, nurses and physicians
por: van Ee, I., et al.
Publicado: (2021)

Long‐term, durable, absolute Psoriasis Area and Severity Index and health‐related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate‐to‐severe plaque psoriasis
por: Gooderham, M., et al.
Publicado: (2022)

Genetic polymorphisms associated with psoriasis and development of psoriatic arthritis in patients with psoriasis
por: Loft, Nikolai Dyrberg, et al.
Publicado: (2018)

Secukinumab efficacy in reducing the severity and the psychosocial impact of moderate‐to‐severe psoriasis as assessed by the Simplified Psoriasis Index: results from the IPSI‐PSO study
por: Richard, M.‐A., et al.
Publicado: (2020)

Network meta‐analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values ≤1, 2, 3 or 5 derived from a statistical conversion method
por: Mrowietz, U., et al.
Publicado: (2021)

Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study
por: Rungapiromnan, W., et al.
Publicado: (2019)

Sleep disorders in patients with psoriatic arthritis and psoriasis
por: Krajewska-Włodarczyk, Magdalena, et al.
Publicado: (2018)

The burden of psoriasis in patients with early psoriatic arthritis
por: Kasiem, Fazira R, et al.
Publicado: (2021)

Diagnostic and therapeutic guidelines for plaque psoriasis - Brazilian Society of Dermatology
por: Arnone, Marcelo, et al.
Publicado: (2019)

Ustekinumab in the Treatment of Psoriasis and Psoriatic Arthritis
por: Savage, Laura J., et al.
Publicado: (2015)

Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis
por: Puig, Lluís
Publicado: (2017)

Psoriasis, Psoriatic Arthritis, and Thyroid Autoimmunity
por: Ruffilli, Ilaria, et al.
Publicado: (2017)

Patient‐reported symptoms and signs of moderate‐to‐severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial
por: Papp, K.A., et al.
Publicado: (2018)

Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER‐3 study
por: Lebwohl, M.G., et al.
Publicado: (2019)

Ixekizumab improves secondary lesional signs, pain and sexual health in patients with moderate‐to‐severe genital psoriasis
por: Merola, J.F., et al.
Publicado: (2020)

Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient‐reported outcomes from a Phase 3 study
por: Valenzuela, F., et al.
Publicado: (2016)

Certolizumab pegol for the treatment of patients with moderate‐to‐severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials
por: Blauvelt, A., et al.
Publicado: (2018)

Screening for Psoriatic Arthritis in Korean Psoriasis Patients Using the Psoriatic Arthritis Screening Evaluation Questionnaire
por: You, Hyang-Suk, et al.
Publicado: (2015)

Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population‐based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey
por: van de Kerkhof, P.C.M., et al.
Publicado: (2015)

Fumaric acid ester‐induced T‐cell lymphopenia in the real‐life treatment of psoriasis
por: Dickel, H., et al.
Publicado: (2019)

PsA-Disk, a novel visual instrument to evaluate psoriatic arthritis in psoriatic patients: an Italian derma-rheuma multicentre study
por: Chimenti, Maria Sole, et al.
Publicado: (2019)

Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate‐to‐severe psoriasis: a pooled analysis of two randomized controlled trials
por: Blauvelt, A., et al.
Publicado: (2019)

The efficacy and safety of apremilast, etanercept and placebo in patients with moderate‐to‐severe plaque psoriasis: 52‐week results from a phase IIIb, randomized, placebo‐controlled trial (LIBERATE)
por: Reich, K., et al.
Publicado: (2016)

Long‐term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open‐label, phase 3 study (UNCOVER‐J)
por: Okubo, Y., et al.
Publicado: (2018)

Image‐based automated Psoriasis Area Severity Index scoring by Convolutional Neural Networks
por: Schaap, M.J., et al.
Publicado: (2021)

Secukinumab significantly reduces psoriasis‐related work impairment and indirect costs compared with ustekinumab and etanercept in the United Kingdom
por: Warren, R.B., et al.
Publicado: (2018)

Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO‐ABLE study
por: Paul, C., et al.
Publicado: (2016)

Risk factors and predictors of psoriatic arthritis in patients with psoriasis
por: Azevedo, Valderilio Feijó, et al.
Publicado: (2013)

Reducing the Risk of Developing Psoriatic Arthritis in Patients with Psoriasis
por: Gisondi, Paolo, et al.
Publicado: (2022)

Phase 3, open‐label, randomized study of the pharmacokinetics, efficacy and safety of ixekizumab following subcutaneous administration using a prefilled syringe or an autoinjector in patients with moderate‐to‐severe plaque psoriasis (UNCOVER‐A)
por: Callis Duffin, K., et al.
Publicado: (2016)

Managing Patients with Psoriatic Disease: The Diagnosis and Pharmacologic Treatment of Psoriatic Arthritis in Patients with Psoriasis
por: Mease, Philip J., et al.
Publicado: (2014)

Cardiovascular risk factors in psoriatic disease: psoriasis versus psoriatic arthritis
por: Barbarroja, Nuria, et al.
Publicado: (2019)

Juvenile Psoriatic Arthritis (JPsA): juvenile arthritis with psoriasis?
por: Butbul Aviel, Yonatan, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_tcierqiej8hlaemjgufelvcfuj